november AG

euro adhoc: november AG
Restructuring & Recapitalisations
Capital Increase entered in commercial register

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

20.11.2007

Erlangen, 20. November 2007. According to the decision made at the last annual shareholder´s meeting on  May 22nd 2007, november AG has successfully completed the capital increase against contribution in kind by contributing the companies IBL Gesellschaft für Immunchemie und Immunbiologie mbH (Hamburg) and PROGEN Biotechnik GmbH, (Heidelberg). Yesterday, these measures were entered in the commercial register by the competent court. The capital stock has now been increased by EUR 10.287.356,00 from EUR 3.754.160,00 to EUR 14.041.516,00.

@@start.t2@@end of announcement                                                 euro adhoc 20.11.2007 11:38:53
--------------------------------------------------------------------------------@@end@@

ots Originaltext: november AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Marcus Weichert
Leitung PR/IR
Telefon: +49(0)9131 75088 868
E-Mail: weichert@november.de

Branche: Biotechnology
ISIN:      DE0006762909
WKN:        676290
Index:    CDAX, Technologie All Share, Prime All Share
Börsen:  Börse Frankfurt / regulated dealing/prime standard
              Börse Berlin / free trade
              Börse Stuttgart / free trade
              Börse Düsseldorf / free trade
              Börse Hannover / free trade
              Börse München / free trade



Weitere Meldungen: november AG

Das könnte Sie auch interessieren: